Inflammation promotes regeneration of injured tissues through poorly understood mechanisms, some of which involve interleukin (IL)-6 family members, the expression of which is elevated in many diseases including inflammatory bowel diseases and colorectal cancer. Here we show in mice and human cells that gp130, a co-receptor for IL-6 cytokines, triggers activation of YAP and Notch, transcriptional regulators that control tissue growth and regeneration, independently of the gp130 effector STAT3. Through YAP and Notch, intestinal gp130 signalling stimulates epithelial cell proliferation, causes aberrant differentiation and confers resistance to mucosal erosion. gp130 associates with the related tyrosine kinases Src and Yes, which are activated on receptor engagement to phosphorylate YAP and induce its stabilization and nuclear translocation. This signalling module is strongly activated upon mucosal injury to promote healing and maintain barrier function.
Inflammation is a complex biological response triggered by tissue damage or microbial invasion. In addition to host defence, self-limiting inflammation triggers regeneration and repair 1, 2 . By preventing further microbial translocation, healing promotes resolution of inflammation. Whereas host defence and immunity have been extensively studied, the mechanisms by which inflammation stimulates regenerative responses remain obscure. Numerous pathways involved in tissue growth, patterning and differentiation are re-deployed during regeneration, including the Hedgehog (Hh)-Gli, Wnt-b-catenin, Notch and Hippo-YAP pathways 3, 4 . Upon tissue injury, myeloid cells, including macrophages, produce inflammatory cytokines and growth factors 5 . However, signalling mechanisms that link typical inflammatory cytokines to pivotal transcriptional regulators of tissue growth, repair and regeneration remain to be charted.
Regenerative responses are particularly important in the mammalian gastrointestinal tract, a tissue subject to frequent erosion and renewal. Unrepaired mucosal injury disrupts the epithelial barrier that prevents translocation of intestinal microbiota, resulting in acute inflammation 6 . Persistent failure to repair such damage can result in inflammatory bowel diseases (IBD), including ulcerative colitis, which entails severe mucosal erosion, and Crohn's disease (CD), in which aberrant growth can cause fistula formation 6 . Mucosal healing is a key treatment goal in IBD that predicts sustained remission and resection-free survival 6 . It is therefore important to understand how mucosal healing is regulated. After injury, intestinal epithelial cells (IECs) surrounding the lesion lose columnar polarity and rapidly initiate wound healing. 'Epithelial restitution' starts within minutes of injury and is considered crucial for temporary sealing of the disrupted surface. Subsequent stem-cell activation, proliferation and differentiation increase the cell pool available for healing. These processes are tightly regulated to prevent uncontrolled proliferation and tumorigenesis, and rely on coordinated and balanced function of IECs, secretory cells, intestinal stem cells and the immune system 6 . IL-6 is a prototypical pro-inflammatory cytokine, with family members including IL-11, IL-27, IL-31, leukaemia inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1, all of which influence cell proliferation, survival, migration, invasion, angiogenesis and inflammation 7 . Most family members activate the JAK-STAT3, SHP2-Ras-ERK and PI(3)K-AKT-mTORC1 pathways via the common co-receptor gp130 (refs 7, 8) . Among these pathways, STAT3 is the major and most extensively studied effector that links inflammation to cell proliferation, survival and cancer, being subject to feedback regulation by suppressor of cytokine signalling 3 (SOCS3) 8, 9 . IL-6, soluble IL-6Ra and IL-11 are highly elevated in IBD and gastrointestinal cancers 10, 11 . However, activating STAT3 mutations are rare 12 , and tumoral STAT3 is mainly activated by cytokines and/or decreased SOCS3 expression 13 . Nonetheless, gain-of-function mutations affecting gp130-STAT3 signalling were identified in benign human inflammatory hepatocellular adenomas (IHCA) 12, 14 . IL-6 promotes IEC proliferation and regeneration, and IL-6-deficient mice, which do not exhibit developmental abnormalities, are highly sensitive to experimental colitis induced by dextran sulfate sodium salt (DSS) 13 . Correspondingly, IL-6 blockade in humans can result in intestinal perforation 15 . In addition to STAT3 in IECs 13 , mucosal regeneration after DSS challenge requires concomitant activation of Yes-associated protein (YAP) 16 and Notch 17 . YAP is a key transcriptional co-activator of tissue growth, which is normally kept inactive in the cytoplasm through serine phosphorylation by the Hippo effector kinase LATS 18 . YAP is activated either upon inhibition of Hippo signalling or upon tyrosine phosphorylation by the Src family kinase (SFK) Yes 19 . Notch is activated by ligands such as Jagged 1, Jagged 2 and Delta-like (DLL) 1, 3 and 4, which trigger Notch cleavage by c-secretase, resulting in nuclear translocation of its intracellular domain (NICD) which associates with CBF1/ RBP-Jk to activate target gene transcription 20 . The mechanisms whereby mucosal injury activates YAP and Notch remain elusive.
We show that independently of STAT3, gp130 also activates YAP and then Notch through direct association with SFKs. This pathway is engaged upon mucosal injury in mice and is essential for inflammationinduced epithelial regeneration; it is also activated in human IBD.
gp130 activation causes aberrant IEC proliferation
We generated villin-gp130
Act transgenic mice that express activated gp130
Act (an in-frame S187-Y190 deletion found in IHCA 14 ) from the IEC-specific villin promoter (Extended Data Fig. 1a, b) . Hemizygous villin-gp130
Act mice were born in Mendelian ratios, but their intestines were larger and longer than wild-type counterparts (Fig. 1a and Extended Data Fig. 1c) . The transgenic intestinal mucosa was hyperproliferative with deeper crypts than wild type (Fig. 1b-d and Extended Data Fig. 1d ), without a difference in apoptosis (Extended Data Fig. 1e ). The villuscrypt structure was disorganized due to increased cell proliferation, but secretory cells (goblet, Paneth and enteroendocrine cells) were markedly decreased in the villin-gp130
Act small intestine (Fig. 1e , f and Extended Data Fig. 1f-h ). Ectopic alkaline phosphatase (AP) staining in villingp130
Act small intestinal crypts suggested abortive differentiation of absorptive enterocytes (Fig. 1g) . Electron microscopy revealed short, thick and non-uniform microvilli, typical of undifferentiated brush border cells (Extended Data Fig. 1i ). Lamina propria CD45
1 immune cells were increased in the villin-gp130
Act intestine, and pro-inflammatory cytokines, such as Il6 and Tnf, were upregulated (Extended Data Fig. 2a, b) . However, more modest differences in the colonic mucosa were found between wild-type and transgenic mice (Extended Data Fig. 2c ), probably because the villin promoter is more active in the small intestine 21 .
gp130 activates YAP and Notch signalling
The gp130 effectors STAT3, STAT1 and ERK1/2 were activated in villingp130
Act mice (Fig. 2a, b and Extended Data Fig. 2d , e). Ribosomal protein S6 phosphorylation, indicating mTORC1 activation, was also elevated in villin-gp130
Act small intestine (Extended Data Fig. 2d ). An increase in undifferentiated, proliferating enterocytes and a decrease in secretory cell lineages are typical of mice with strongly activated YAP or Notch [22] [23] [24] , whereas Notch/c-secretase inhibition converts proliferative IECs into goblet cells 25 . YAP and its target, connective tissue growth factor (CTGF), and the Notch target HES1 were strongly elevated in villin-gp130
Act small intestine, along with higher amounts of activated b-catenin (Fig. 2a) . YAP was mainly found in IEC nuclei in villi and crypts (Fig. 2b) , as well as in colon (Extended Data Fig. 2e ). Nuclear HES1 was also elevated in villin-gp130
Act small intestinal crypts (Fig. 2b ) and strong nuclear YAP staining was observed in villin-gp130
Act intestinal organoids (Fig. 2c) , a useful ex vivo system for studying IEC signalling 26 . Yap mRNA expression remained unchanged (Extended Data Fig. 3a) , suggesting post-transcriptional regulation. Ctgf and Hes1, however, were upregulated at the mRNA level along with mRNAs for intestinal stemcell markers, Cd44 and Cd133, and Notch ligands and receptors (Extended Data Fig. 3a , b). Transgenic intestinal organoids at day 3 after passage formed more rounded structures, although no morphological difference was seen between them and wild-type organoids on day 6 (Extended Data Fig. 3c ). Rounded organoids form upon b-catenin activation 27 , suggesting more active Wnt signalling in villin-gp130
Act organoids. YAP and Notch were also activated in human colorectal cancer (CRC) cells expressing a gp130 superactive variant (gp130 SA ), which is refractory to feedback inhibition by SOCS3 due to an additional Y759F substitution (Extended Data Figs 1a and 3d). CD44 cleavage, another c-secretasemediated event 28 , was upregulated in transgenic small intestine and RESEARCH ARTICLE organoids (Fig. 2d and Extended Data Fig. 2d ). IL-6 activated YAP and STAT3 in human CRC cells and mouse primary hepatocytes (Extended Data Figs 3e-g ).
Transcriptomic analysis confirmed the above results by showing strong enrichment for genes associated with innate immune response, response to viral infection and defence response in transgenic crypts (Extended Data Fig. 3h ). Similar observations were made in IHCA patients with gp130 activating mutations 14 . The growth factor amphiregulin (Areg), another YAP target 29 , was upregulated in both villingp130
Act intestinal crypts and organoids (Extended Data Fig. 3h, i) .
Notch or YAP inhibition restores IEC homeostasis
We examined whether Notch or YAP inhibition restored epithelial homeostasis in transgenic mice. To block Notch (and CD44) signalling we injected mice with a c-secretase inhibitor, dibenzazepine (DBZ), and found that it restored secretory cell lineages, blocked HES1 expression and partially suppressed hyperproliferation and YAP activation (Fig. 3a, b and Extended Data Fig. 4a ). To delete YAP in IECs, we crossed villin-gp130 Act mice with villin-cre 3 Yap fl/fl (Yap DIEC ) mice. YAP ablation largely restored secretory cell lineages and suppressed hyperproliferation and HES1 expression (Fig. 3c, d and Extended Data Fig. 4b ). TAZ, a paralogue that partially compensates for YAP loss 30 , was upregulated in the absence of YAP (Fig. 3e) , possibly explaining the incomplete reversal of the villin-gp130
Act phenotype. We also investigated the contribution of other well-established gp130 effector pathways. We crossed villin-gp130
Act and villin-cre 3 Stat3 fl/fl (Stat3 DIEC ) mice. Notably, STAT3 ablation did not affect the villin-gp130
Act phenotype (Extended Data  Fig. 4c ). MEK (PD0325901) or PI(3)K (LY294002) inhibitors also did not reverse the villin-gp130
Act phenotype, although they both inhibited their targets (Extended Data Fig. 5a, b) .
YAP upregulation by gp130-mediated SFK activation
We did not detect a decrease in YAP or LATS serine phosphorylation that could explain YAP activation in villin-gp130
Act IECs. On the contrary, both LATS and YAP S127 phosphorylation were elevated, suggesting enhanced Hippo activity (Fig. 2a and Extended Data Fig. 6a ). Since Y357 phosphorylation by Yes activates YAP 19 , we checked whether SFKs were activated in the transgenic small intestine. Human SFKs are positively regulated by Y419 phosphorylation and inhibited by Y530 phosphorylation 31 . Src/Yes Y419 was hyper-phosphorylated and Y530 was under-phosphorylated in villin-gp130
Act IECs (Fig. 4a) . SFK activation was also observed in villin-gp130
Act intestinal organoids (Fig. 4b) , human colon cancer cells overexpressing gp130
Act or stimulated with IL-6, correlating with YAP Y357 phosphorylation (Extended Data Figs 3e and 6b). YAP Y357 was also phosphorylated upon gp130
Act expression in intestinal organoids or human colon cancer cells (Fig. 4b and Extended Data Fig. 6c, d ), after IL-11 stimulation (Extended Data Fig. 6e ), or in primary hepatocytes stimulated with IL-6 and mouse liver undergoing partial hepatectomy, which also exhibited Notch and SFK activation (Extended Data Fig. 3g, 6f ). YAP and Notch activation in liver were inhibited by treatment with the Src inhibitor PP2, indicating SFK dependence (Extended Data Fig. 6f ). Y357 phosphorylation increases YAP protein stability 32 . Indeed, Src, but not JAK, inhibition accelerated YAP degradation in cycloheximide-treated cells (Extended Data Fig. 6g ). Src inhibition also decreased YAP in organoids (Extended Data Fig. 7d ), whereas Src activation enhanced YAP expression (Extended Data Fig. 6h) . Notably, elevated Src Y419 phosphorylation and YAP expression were detected in approximately 60% of colonic biopsies collected from CD patients ( Fig. 4d and Extended Data Table 1 ). Both SFK phosphorylation and YAP upregulation correlated with active disease.
Notably, gp130 interacted with endogenous Src and Yes, and both gp130 and YAP co-immunoprecipitated with Src ( Fig. 4e and Extended Data Fig. 6i ). Deletion of gp130 amino acids 812-827, which contain a phosphotyrosine motif, reduced binding to Src and attenuated activation of Src, YAP and Notch, but not STAT3 (Fig. 4f and Extended Data Fig. 6j, k) . These data suggest that gp130 activates YAP through its interaction with SFK, independently of STAT3. Treatment of villin-gp130 Act mice with PP2 restored secretory cell lineages and inhibited IEC hyperproliferation, Src Y419 phosphorylation, HES1 expression, as well as ERK and YAP activation with only a modest effect on STAT3 (Fig. 4c and Extended Data Fig. 7a ). PP2 and another SFK inhibitor (AZD0530), but not a JAK inhibitor (AZD1480) or DBZ, suppressed nuclear YAP in villin-gp130
Act intestinal organoids ( Fig. 4g and Extended Data Fig. 7b, c) . Consistent with a recent report that YAP potentiates b-catenin activation 33 , villin-gp130
Act organoids contained more activated b-catenin than wild-type organoids, and Src inhibition reversed this effect (Extended Data Fig. 7d) . Src, but not JAK inhibitors, blocked IL-6-or gp130 Act -induced YAP activation and stabilization in human CRC cells and mouse small intestinal organoids (Extended Data Fig. 7d-f ).
gp130-SFK-YAP signalling aids mucosal regeneration
To examine gp130-SFK-YAP signalling during intestinal regeneration, we induced mucosal erosion with DSS. villin-gp130
Act mice exhibited less severe colitis and weight loss than wild-type mice, as well as reduced colon shortening and improved crypt architecture (Fig. 5a and Extended Data Fig. 8a, b) , which are the opposite phenotypes of IEC-specific STAT3 or YAP deficiencies 13, 16 . The colonic epithelium of villin-gp130
Act mice showed more proliferation and less apoptosis during DSS colitis (Fig. 5b and Extended Data Fig. 8c) , as well as elevated STAT3, SFK and YAP ARTICLE RESEARCH phosphorylation and Notch activation (Fig. 5c) . Notch receptors and ligands were elevated in villin-gp130
Act colons and their expression decreased upon YAP, but not STAT3, ablation (Extended Data Fig. 8d ).
villin-gp130
Act mice also showed an improved gut barrier function, despite no obvious differences in IEC tight junctions relative to wild-type mice (Extended Data Fig. 8e-g ). DSS treatment induced IL-6 family cytokines in the colon and led to strong SFK-YAP and STAT3 activation (Extended Data Fig. 8h, i) . Inhibition of SFK signalling with PP2 during DSS challenge suppressed intestinal regeneration (Fig. 5e, f and Extended Data Fig. 8j ). IEC-specific YAP or STAT3 ablation in villin-gp130
Act mice increased DSS-induced weight loss and tissue damage (Fig. 5g ). By contrast, gp130
Act conferred DSS resistance on Yap DIEC and Stat3 DIEC mice, although not as strongly as its effect in wild-type mice (Extended Data  Fig. 9a) . Thus, both YAP and STAT3 contribute to mucosal regeneration. However, YAP was not required for STAT3 activation and STAT3
was not needed for YAP and Notch activation, and neither YAP nor STAT3 affected SFK activation (Fig. 5d) . YAP, but not STAT3, was required for induction of Notch ligands and receptors, although STAT3 was essential for Bcl2 and Bcl-X L induction (Extended Data Fig. 9b) .
We examined whether gp130 signalling controls wound healing in the absence of inflammation. Expression of gp130
Act in rat IEC6 cells enhanced wound closure after monolayer scratching (Extended Data  Fig. 9c ). This effect was attenuated by Src, YAP and Notch inhibitors but hardly influenced by a JAK inhibitor. Silencing of YAP also attenuated wound closure, although it did not inhibit Src activation (Extended Act (D771-811) or gp130 Act (D812-827) lentiviruses were prepared and subjected to immunoblot analysis with the indicated antibodies. g, Wild-type and villin-gp130
Act small intestinal organoids were treated with DMSO and PP2 (10 mM) for 24 h, stained with YAP antibody and counter stained with DAPI. Scale bars represent 100 mm (a, c, d, g ) and all data are representative of at least 2-3 independent experiments. RESEARCH ARTICLE Data Fig. 9d, e) . Together, these data support the signalling scheme outlined in Extended Data Fig. 9f and indicate that once gp130 is activated it can contribute to healing, regeneration and termination of inflammation via the SFK-YAP-Notch cascade in addition to its well-established effect on STAT3, even without ongoing inflammation. , and activate YAP through Y357 phosphorylation 19 ; thereby stabilizing the protein and increasing its nuclear concentration. It would be interesting to examine the effect of SH3bm inactivation on intestinal regeneration, as long as such mutations do not interfere with other aspects of YAP regulation. Another, but less direct, link between gp130 and YAP may be provided by SHP2, the subcellular distribution of which is controlled through interaction with YAP and TAZ
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. By binding transcription factors, such as TEAD 18 , YAP controls genes that stimulate cell proliferation and tissue growth and inhibit terminal differentiation 22 . Such genes include the growth factors CTGF and Areg 29 and the Notch ligand Jagged 1 36 , whose expression is upregulated in the villin-gp130
Act intestinal epithelium, along with Notch 1, Notch 3 and DLL3. This results in Notch activation, which can further sustain YAP activity 37 . Although YAP and Notch are required for mucosal regeneration 16, 17 , the mechanisms responsible for their activation upon injury and inflammation were heretofore unknown. Until recently, activation of YAP was believed to solely depend on inhibition of Hippo signalling that retains YAP in the cytoplasm 18 . Only recently, G-proteincoupled receptors were found to activate YAP through a partially understood Hippo-independent mechanism 38 , and in cancer cells Yes was demonstrated to activate YAP via tyrosine phosphorylation 19 . However, the physiological role of YAP tyrosine phosphorylation in normal tissues remained unknown. We now show that SFK-induced YAP activation, rather than Hippo inhibition, is critical for regeneration of the injured intestinal mucosa. The same pathway is activated after partial hepatectomy and may contribute to liver regeneration. YAP Y357 phosphorylation may also be regulated by the tumour suppressor RASSF1A, but its effect may be indirect as Rassf1a 2/2 mice exhibit elevated IL-6 production after DSS-induced injury 39 . The IL-6 family member LIF stimulates self-renewal of cultured embryonic stem cells through a gp130-Yes-YAP module 40 , but the in vivo relevance of this finding was not established. STAT3 was also suggested to maintain embryonic stem cell pluripotency 41 . Thus, it is plausible that gp130-activating cytokines are general regulators of tissue homeostasis and regeneration. Expression of IL-6 family members is elevated in a number of chronic inflammatory diseases and gastrointestinal cancers 42 , and our results demonstrate frequent SFK and YAP activation in CD. Although previous efforts in targeting the pro-tumorigenic activity of IL-6-related cytokines had focused on the JAK-STAT3 module 43 , it should be noted that Yes and Src are often activated in CRC, even though the cause of their activation was not identified 31, 44 . Furthermore, Src controls intestinal regeneration in both mice and flies 44 . We suggest that SFK activation during IBD regeneration and CRC is caused by IL-6 family members. Nonetheless, villin-gp130 Act mice do not develop malignant tumours before 12 months of age, indicating that chronic YAP, Notch and STAT3 activation are insufficient for oncogenic transformation.
Persistent YAP and Notch activation results in skewed differentiation of intestinal stem cells, entailing expansion of immature enterocytes and under-representation of secretory cell types. The paucity of Paneth and goblet cells in villin-gp130
Act mice resembles their deficiency in IBD, which may reflect chronic elevation of IL-6 or IL-11 and persistent Src and YAP activation. Nonetheless, despite the deficiency in defensin-producing Paneth cells and mucin-producing goblet cells, villin-gp130
Act mice display an improved gut barrier function, underscoring the importance of epithelial regeneration in preventing excessive microbial translocation. Thus, future therapeutic efforts in IBD should aim at normalizing IL-6 cytokine expression, rather than complete blockade, thereby restoring immune and epithelial homeostasis.
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